Search Results - "Subbiah, Vivek"

Author Index.

Authors: Hansen, Alexandra

Source: Quality of Life Research. 2022 Suppl, Vol. 31, p171-187. 17p.

Subjects: Quality of Life Research (Periodical), Authors

Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?

Authors: Desai, Aakash Subbiah, Vivek Roy-Chowdhuri, Sinchita et al.

Source: Cancers. Nov2024, Vol. 16 Issue 22, p3753. 8p.

Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer.

Authors: Lin, Edwin Lo, Ying-Chun Subbiah, Vivek et al.

Source: Experimental Hematology & Oncology. 7/11/2025, Vol. 14 Issue 1, p1-5. 5p.

Author index.

Source: Quality of Life Research. Oct2021 Supplement 1, Vol. 30 Issue 1, p179-196. 18p.

Subjects: Chinese martial arts

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.

Authors: Subbiah, Vivek Dumbrava, Ecaterina Ileana Jiang, Yunfang et al.

Source: Experimental Hematology & Oncology. 4/20/2020, Vol. 9 Issue 1, p1-8. 8p.

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.

Authors: Alhalabi, Omar Gouda, Mohamed A. Milton, Denái R. et al.

Source: Cancer Medicine. Feb2025, Vol. 14 Issue 4, p1-12. 12p.

Author index.

Source: Quality of Life Research. Oct2019 Supplement 1, Vol. 28 Issue 1, p191-209. 19p.

Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.

Authors: Murray, Suzanne Subbiah, Vivek Sherman, Steven I. et al.

Source: Thyroid Research. 8/14/2023, Vol. 16 Issue 1, p1-12. 12p.

Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis.

Authors: Kairemo, Kalevi Macapinlac, Homer A. Gouda, Mohammed et al.

Source: Diagnostics (2075-4418). Sep2024, Vol. 14 Issue 17, p1886. 9p.

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.

Authors: Moussa, Mohammad Jad Khandelwal, Jaanki Wilson, Nathaniel R. et al.

Source: Current Oncology. Jun2024, Vol. 31 Issue 6, p3342-3349. 8p.

Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors.

Authors: Kairemo, Kalevi Gouda, Mohamed Chuang, Hubert H. et al.

Source: Journal of Clinical Medicine. Jun2024, Vol. 13 Issue 11, p3269. 9p.

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.

Authors: Wagner, Michael J. Hennessy, Cassandra Beeghly, Alicia et al.

Source: Cancers. Sep2022, Vol. 14 Issue 17, p4334. 13p.

Data-Driven Modeling and Design of Sustainable High Tg Polymers.

Authors: Liu, Qinrui Forrester, Michael F. Dileep, Dhananjay et al.

Source: International Journal of Molecular Sciences. Mar2025, Vol. 26 Issue 6, p2743. 15p.

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.

Authors: Thein, Kyaw Z. Piha-Paul, Sarina A. Tsimberidou, Apostolia et al.

Source: Experimental Hematology & Oncology. 12/29/2021, Vol. 10 Issue 1, p1-6. 6p.

Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer - Authors' reply.

Authors: Subbiah, Vivek Lassen, Ulrik Gasal, Eduard et al.

Source: Lancet Oncology. Nov2020, Vol. 21 Issue 11, pe516-e516. 1p.

STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Authors: Subbiah, Vivek McMahon, Caitlin Patel, Shreyaskumar et al.

Source: Journal of Hematology & Oncology. 2015, Vol. 8 Issue 1, p1-7. 7p.

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.

Authors: Nelson, Blessie Elizabeth Roszik, Jason Ahmed, Jibran et al.

Source: Molecular Cancer. 3/26/2024, Vol. 23 Issue 1, p1-11. 11p.

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors.

Authors: Coleman, Niamh Stephen, Bettzy Fu, Siqing et al.

Source: Cancer Medicine. Feb2024, Vol. 13 Issue 3, p1-11. 11p.

Food and Drug Administration approvals in phase 3 Cancer clinical trials.

Authors: Abi Jaoude, Joseph Kouzy, Ramez Ghabach, Marc et al.

Source: BMC Cancer. 6/12/2021, Vol. 21 Issue 1, p1-6. 6p.

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response.

Authors: Persha, Hanna E. Kato, Shumei De, Pradip et al.

Source: Journal of Hematology & Oncology. 8/28/2022, Vol. 15 Issue 1, p1-5. 5p.